The Role of MiR-128 in Cancer Development, Prevention, Drug Resistance, and Immunotherapy

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Feb 16

PMID 36793341

Authors

Hendrik Setia Budi

Laith A Younus

Methaq Hadi Lafta

Sameena Parveen

Hawraa Jabbar Mohammad

Zahraa Haleem Al-Qaim

Mohammed Abed Jawad

Rosario Mireya Romero Parra

Yasser Fakri Mustafa

Firas Rahi Alhachami

Sajad Karampoor

Rasoul Mirzaei

Affiliations

Soon will be listed here.

Abstract

A growing body of evidence has revealed that microRNA (miRNA) expression is dysregulated in cancer, and they can act as either oncogenes or suppressors under certain conditions. Furthermore, some studies have discovered that miRNAs play a role in cancer cell drug resistance by targeting drug-resistance-related genes or influencing genes involved in cell proliferation, cell cycle, and apoptosis. In this regard, the abnormal expression of miRNA-128 (miR-128) has been found in various human malignancies, and its verified target genes are essential in cancer-related processes, including apoptosis, cell propagation, and differentiation. This review will discuss the functions and processes of miR-128 in multiple cancer types. Furthermore, the possible involvement of miR-128 in cancer drug resistance and tumor immunotherapeutic will be addressed.

Citing Articles

Bee Pollen Phytochemicals and Nutrients as Unequaled Pool of Epigenetic Regulators: Implications for Age-Related Diseases.

Kacemi R, Campos M Foods. 2025; 14(3).

PMID: 39941940 PMC: 11816923. DOI: 10.3390/foods14030347.

miR-128-3p suppresses tumor growth and enhances chemosensitivity in tongue squamous cell carcinoma through MAP2K7 targeting.

Gupta P, Mallick B Mol Biol Rep. 2024; 51(1):1107.

PMID: 39476205 DOI: 10.1007/s11033-024-10040-7.

Exploring miRNA therapies and gut microbiome-enhanced CAR-T cells: advancing frontiers in glioblastoma stem cell targeting.

Sandhanam K, Tamilanban T, Bhattacharjee B, Manasa K Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39382681 DOI: 10.1007/s00210-024-03479-9.

miRNA-Mediated Mechanisms in the Generation of Effective and Safe Oncolytic Viruses.

Toropko M, Chuvpilo S, Karabelsky A Pharmaceutics. 2024; 16(8).

PMID: 39204331 PMC: 11360794. DOI: 10.3390/pharmaceutics16080986.

MicroRNA-Dependent Mechanisms Underlying the Function of a β-Amino Carbonyl Compound in Glioblastoma Cells.

Mustafov D, Siddiqui S, Kukol A, Lambrou G, Shagufta , Ahmad I ACS Omega. 2024; 9(29):31789-31802.

PMID: 39072119 PMC: 11270567. DOI: 10.1021/acsomega.4c02991.

References

Peng Y, Croce C . The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2017; 1:15004. PMC: 5661652. DOI: 10.1038/sigtrans.2015.4. View

Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F . MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ. 2011; 19(6):1038-48. PMC: 3354056. DOI: 10.1038/cdd.2011.190. View

Bruno I, Karam R, Huang L, Bhardwaj A, Lou C, Shum E . Identification of a microRNA that activates gene expression by repressing nonsense-mediated RNA decay. Mol Cell. 2011; 42(4):500-10. PMC: 3123134. DOI: 10.1016/j.molcel.2011.04.018. View

Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

Bol K, Aarntzen E, In t Hout F, Schreibelt G, Creemers J, Lesterhuis W . Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology. 2016; 5(1):e1057673. PMC: 4760342. DOI: 10.1080/2162402X.2015.1057673. View

Fu C, Li D, Zhang X, Liu N, Chi G, Jin X . LncRNA PVT1 Facilitates Tumorigenesis and Progression of Glioma via Regulation of MiR-128-3p/GREM1 Axis and BMP Signaling Pathway. Neurotherapeutics. 2018; 15(4):1139-1157. PMC: 6277294. DOI: 10.1007/s13311-018-0649-9. View

Lippman S, Sudbo J, Hong W . Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol. 2005; 23(2):346-56. DOI: 10.1200/JCO.2005.09.128. View

Costinean S, Sandhu S, Pedersen I, Tili E, Trotta R, Perrotti D . Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood. 2009; 114(7):1374-82. PMC: 2727407. DOI: 10.1182/blood-2009-05-220814. View

Pirker R . What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?. Future Oncol. 2015; 11(1):153-67. DOI: 10.2217/fon.14.178. View

10.

Schinkel A . The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers. Adv Exp Med Biol. 2002; 500:365-72. DOI: 10.1007/978-1-4615-0667-6_60. View

11.

Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B . BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003; 95(8):625-7. DOI: 10.1093/jnci/95.8.625. View

12.

Pui C, Chessells J, Camitta B, Baruchel A, Biondi A, Boyett J . Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia. 2003; 17(4):700-6. DOI: 10.1038/sj.leu.2402883. View

13.

Abedalthagafi M, Barakeh D, Foshay K . Immunogenetics of glioblastoma: the future of personalized patient management. NPJ Precis Oncol. 2018; 2:27. PMC: 6279755. DOI: 10.1038/s41698-018-0070-1. View

14.

Rowley J . Molecular genetics in acute leukemia. Leukemia. 2000; 14(3):513-7. DOI: 10.1038/sj.leu.2401600. View

15.

Lowenberg B, Downing J, Burnett A . Acute myeloid leukemia. N Engl J Med. 1999; 341(14):1051-62. DOI: 10.1056/NEJM199909303411407. View

16.

Zhao J, Li D, Fang L . MiR-128-3p suppresses breast cancer cellular progression via targeting LIMK1. Biomed Pharmacother. 2019; 115:108947. DOI: 10.1016/j.biopha.2019.108947. View

17.

Chen H, Zhou L, Dou T, Wan G, Tang H, Tian J . BMI1'S maintenance of the proliferative capacity of laryngeal cancer stem cells. Head Neck. 2011; 33(8):1115-25. DOI: 10.1002/hed.21576. View

18.

Turashvili G, Lightbody E, Tyryshkin K, SenGupta S, Elliott B, Madarnas Y . Novel prognostic and predictive microRNA targets for triple-negative breast cancer. FASEB J. 2018; :fj201800120R. DOI: 10.1096/fj.201800120R. View

19.

Xiao M, Lou C, Xiao H, Yang Y, Cai X, Li C . MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer. Br J Surg. 2017; 105(1):75-85. DOI: 10.1002/bjs.10646. View

20.

Pasieka J . Anaplastic thyroid cancer. Curr Opin Oncol. 2002; 15(1):78-83. DOI: 10.1097/00001622-200301000-00012. View